GLP-1 Therapies Emerge as Key Tools in CKD Prevention—But Long-Term Success Hinges on Patient Engagement
As reported on Healio, glucagon-like peptide-1 (GLP-1)–based therapies are rapidly reshaping the landscape of diabetes and chronic kidney disease (CKD) management. Originally developed for glycemic control, these agents now play…